

Review Article Emergence of third generation tetracyclines: New magic bullets to tackle antibiotic resistance in the post-antibiotic era

ABSTRACT

Antibiotics are the drugs that are used to treat bacterial infections and they don't show any effect on viral infections. Tetracyclines are broad-spectrum antibiotics effective against a wide variety of microorganisms including bacteria, both Gram-positive and Gram-negative, mycoplasmas, rickettsiae, chlamydiae, and protozoan parasites. Owing to their broad spectrum antimicrobial activities and inexpensiveness, tetracyclines have been used extensively in both humans and animal infections and in animal feed as growth promoters. The antimicrobial activities of tetracyclines are subject to both class-specific and intrinsic antimicrobial resistance (AMR) mechanisms. Among all antibiotics, the tetracyclines have acquired much attention due to optimization of their chemical structures that paved way to develop and introduce third generation modern tetracyclines tigecycline in the recent past, followed by omadacycline, eravacycline, and sarecycline recently. Intriguingly, these novel tetracyclines are unique in two ways, first, these are highly effective against pathogens that acquired tetracycline-class resistance and second, these agents exhibit either narrow or broad spectrum of *in vitro* activity against Gram-positive, Gram-negative, anaerobic, and atypical pathogens, including many drug-resistant strains lead to approval for limited use and unique indications. These beneficial effects represent a new era in the rational use of newer tetracyclines, the new magic bullets to tackle AMR in the post-antibiotic era. The present review focuses on third generation tetracyclines emphasizing on their safety, efficacy, and therapeutic choices in various clinical conditions of in-patient and out-patient settings.

Keywords: Antimicrobial resistance, Eravacycline, Multidrug resistance, Omadacycline, Sarecycline, Tigecycline, Tetracyclines, Third generation

1. INTRODUCTION

Pre-antibiotic era is the period before the discovery and potential use of first antibiotic wherein the understanding and knowledge about microbes and infectious diseases were inadequate. During this period, epidemics, morbidity, and mortality due to infectious diseases were common due to lack of successful approaches for treatment and prevention of spread of contagious diseases [1,2]. Since Paul Ehrlich's discovery of salvarsan in 1909 for the treatment of syphilis has led to the basis of the concept of chemotherapy. This chemical, also known as compound 606 or arsphenamine, is widely termed as the first magic bullet [2-4]. Several chemicals with disinfectant and bacteriostatic potential have been developed and their uses in antimicrobial chemotherapy are the milestone in the history of modern medicine and these agents are life-saving weapons against numerous infectious diseases. An antibiotic was a substance produced by one microorganism that selectively inhibits the growth of another or kills another microorganism. Antibiotics were initially viewed

Comment [w1]: Start of new sentence

as 'Wonder Drugs' primarily because these were introduced at a time when only surgical drainage or spontaneous cures were available to treat serious bacterial infections [2,4-6]. The mid-20th century was named the "antibiotic era", and infectious diseases were believed to be eradicated by the end of the last century [1,6]. Contrary to the original belief, over a period of 50 years since the first antibiotic approved for human use, many antibiotics lost efficacy due to safety concerns and development and spread of antimicrobial resistance (AMR). Many microorganisms are continuously evolving and developing resistance and such resistant pathogens, 'superbugs', are rendering previously active antibiotics into ineffective [1,5,6]. Much of the medical and pharmaceutical research and development has been focused on life style disorders and cancer and not many antibiotics were approved since 1980s entering the 'post-antibiotic era' wherein resources for active and effective antibiotics are limited.

1.1 Irrational use of antibiotics

It is highly essential to use antibiotics prophylactically in hospitalized patients for various surgeries, therapeutically in primary care settings for various community acquired infections (CAIs), to prevent and treat infections in various invasive procedures and hospital acquired infections (HAIs) adhere to international, national and hospital antibiotic use policies [7-10]. Moreover, antibiotic use is compulsory in certain unavoidable clinical conditions, such as sepsis and in immunocompromised patients who are at risk of developing mixed infections [9-12]. Inarguably, when there are no clinical practice guidelines, there is need and necessary to prophylactic as well as therapeutic use of antibiotics in the recent unprecedented pandemic time due to coronavirus disease (COVID-19) and in multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2, the virus that causes COVID-19 [11,12]. However, inappropriate and irrational use, such as incorrect use, misuse, overuse, and often real abuse of antibiotics lead to the development of tolerance or antibiotic resistance from the time it is first employed [2,13].

Indeed, antibiotic consumption most prevalent in many developing and developed countries and India is among the highest use in the world and antibiotics sales continue to peak rapidly despite the prevalence of infectious diseases remained stagnant [10,11,14]. It is a well known fact that bacteria survive antibiotics challenges by selection pressure, undergo mutations, evolve as resistant, and regrow are one of the greatest life threats to human health. Consequently, the use of antibiotics is compromised and several microorganisms, including bacteria are developing and spreading antibiotic resistance. However, inappropriate and irrational use, such as incorrect use, misuse, overuse, and often real abuse of antibiotics lead to the development of tolerance or antibiotic resistance from the time it is first employed [2,11,13]. Indeed, antibiotic consumption most prevalent in many developing and developed countries and India is among the highest use in the world and antibiotics sales continue to peak rapidly despite the prevalence of infectious diseases remained stagnant [14-16]. Therefore, AMR is increasing worldwide due to increased prescription and dispensing of antibiotics and is now considered as a global health and developmental threat.

Comment [w2]: Repetition

1.2 Antimicrobial resistance

AMR occurs when microbes, such as bacteria, viruses, fungi, and parasites undergo mutations due to selection pressure and rapidly evolve, and develop resistance that make several previously effective medications into ineffective and render such infections untreatable. The term antibiotic resistance is a subset of AMR, as it applies to bacteria that become resistant to antibiotics. Resistant microbes are more difficult to treat, it requires higher doses, alternative medications, and multidrug treatment which may prove more toxic and may also be more expensive. In 2019 alone, an estimated 4.95 million deaths

associated with bacterial AMR that also implies the economic burden of the country [16-18]. Among the antibiotic-resistant bacteria, 'ESKAPE' pathogens, including, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and, Enterobacter species, cause the majority of hospital infections with a higher rate of mortality [19]. In addition, other pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant enterococci (VRE), effectively escape the effects of many antibacterial drugs which may lead to a longer hospital stay and decreasing workforce productivity [20]. Moreover, most of the microbes exposed to one class of antimicrobials for longer period develop AMR wherein cross-resistance becomingly troublesome. Microbes resistant to multiple antimicrobials (at least three different classes of antimicrobials) are called multidrug-resistant (MDR). Those bacteria that are considered extensively drug-resistant (XDR) or totally drug-resistant (TDR) are sometimes called 'superbugs' [8,9,21]. There is a high risk of entering into a "post-antibiotic era", a period in which bacteria have become resistant to existing antibiotics and the antibiotics no longer work [13,22].

Comment [w3]: Check the correct spelling

1.3 WHO Global Action Plan to tackle antimicrobial resistance

In order to tackle AMR, the World Health Organization (WHO) has developed Global Action Plan in 2015 keeping view of implementation in various nations across the world [23]. This plan is based on 5 objectives, includes first, to improve awareness and understanding of AMR, second, to strengthen knowledge and generate large amount of data, third, to reduce the incidence of infections through effective hygiene measures and good hygiene practice, fourth, to optimize the use of antimicrobial drugs in human and animal health by surveillance and stewardship programs, and fifth, to increase investment in new drugs, diagnostic tools, vaccines, and other interventions for discovery and development of new treatment modalities. In 2016, WHO listed the world's leading antibiotic-resistant bacteria and priority pathogens, for which there is an utmost need for new antibacterial agents for effective treatments against superbugs, MDR and XDR pathogens that are resistant to traditional antibiotics [11,13,22,23]. Since 2017, U.S. Food and Drug Administration (FDA) and the European Medical Agency (EMA) have approved several new antibiotics with predominant activity against Gram-negative bacteria, include plazomicin, eravacycline, cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam (combination of beta-lactam with beta-lactamase inhibitors), imipenem-cilastatin/relebactam, and temocillin, a beta-lactam antibiotic effective against Gram-negative bacteria [1,6,24].

2. TETRACYCLINE ANTIBIOTICS

Tetracyclines have been one of the first antibiotics used to treat infections, they possess many properties considered ideal for antibiotic drugs, including a broad spectrum of activity against Gram-positive and Gram-negative pathogens, proven clinical safety, acceptable tolerability, low adverse effect profile, and availability of intravenous and oral formulations for most members of the class [25,26]. Tetracyclines are divided into three generations based on their spectrum of activity, and pharmacological properties such as a half-life and binding to protein in serum (Table 1) [17,27].

Comment [w4]: Plasma protein instead

2.1 Development of tetracycline antibiotics

Serendipitous discovery and extended use of earlier penicillins and streptomycin in the early 1940s has broadened the scope of identifying and developing newer antibiotics. With the advances of microbiology, biochemistry, and fermentation technology, several pharmaceutical scientists and academic researchers have focused on identifying several lesser known microbes from soil samples collected across the globe, started isolating and

discovering new antibiotics produced by such microorganisms. Owing to these efforts, aureomycin, the first tetracycline was discovered in 1945 lead to series of tetracyclines development during the last century. Chlortetracycline is the synthetic form of aureomycin, natural tetracycline antibiotic, which was discovered at Lederle Laboratories under the supervision of scientist Yellapragada Subbarow and Benjamin Minge Duggar [1,3,17]. Aureomycin was extracted from *Streptomyces aureofaciens* was approved by the FDA in 1948 for medical use in humans. In the following years, terramycin, the second tetracycline, obtained from *Streptomyces rimosus* and its synthetic form oxytetracycline were discovered and approved for human use in 1950 [3,17,25]. Molecular optimizations and structural changes in chlortetracycline lead to the discovery of tetracycline in 1953. Owing to favorable pharmacokinetic profile and enhanced water solubility, tetracycline is considered as widely successful first generation tetracyclines. The second generation tetracyclines include methacycline, doxycycline, and minocycline were approved due to reduced risk of toxicity, better pharmacokinetic profiles, extended antimicrobial spectrum were approved in the early 1970s (Table 1 and Table 2) [2,27,28].

Table 1. Classification of tetracycline based on generations

Generation	Obtaining method	Agents
First	Biosynthesis	Chlortetracycline, oxytetracycline, tetracycline, demeclocycline
Second	Semi-synthesis	Doxycycline, minocycline, lymecycline, medocycline, methacycline, rolitetracycline
Third	Semi-synthesis Total synthesis	Tigecycline, omadacycline, sarecycline Eravacycline

2.2 The discovery of third generation tetracyclines

With the emergence of antibiotic resistance in recent times, there is an urgent need for research, and development and discovery of new antibiotics. Indeed, antibiotic-resistant Enterobacteriaceae and *Acinetobacter baumannii* are problematic pathogens, with only few treatment options for multidrug-resistant (MDR) *A. baumannii* and few oral options for extended spectrum β -lactamase (ESBL)-producing and MDR-Enterobacteriaceae [19,20]. In particular, owing to extensive use of tetracyclines, these pathogens are becoming resistant to many older generation tetracyclines and further hampered by undesired classical side effects. These factors lead to the renewed interest in the development of new tetracyclines. Notably, molecular optimizations and structural changes with the addition of glyceryl moiety led to the discovery of a novel class of aminotetracyclines, known as glycerylcycline [24,27]. Novel tetracyclines include derivatives with more or less similar chemical structures include tigecycline and recently approved omadacycline, eravacycline, and sarecycline that are categorized as the third generation tetracyclines. These newer agents had high potency and increased efficacy with unique antimicrobial spectrum, even against bacteria resistant to older tetracyclines [24,28]. The generation and antibacterial spectrum, pharmacokinetics, dosage regimen, safety, and indications of newer tetracyclines are summarized in Table 1 and Table 2. [??????]

2.3 Mechanism of action of tetracyclines

Tetracyclines inhibit protein synthesis by inhibiting the association of aminoacyl-tRNA with the bacterial ribosome and binding with high affinity to a 30s ribosomal subunit during translation. Then the penetration of aminoacyl-tRNA into the acceptor site (A) on the

bacterial ribosome is blocked, which leads to the cessation in the incorporation of amino acid residues in the process of elongation of the polypeptide chain (Figure 1). Thus, the bacteriostatic activity of antibiotics is achieved by stopping protein synthesis [28,29].

There are **a few newer tetracycline drugs** that are mostly used to treat specific microbes resistant to antibiotics. Similar to the classical tetracyclines, tigecycline, the first of the new generation tetracyclines, exhibits broad-spectrum antibacterial activity. Moreover, the three newer agents approved eravacycline, sarecycline, and omadacycline showed extended and unique antibacterial activity retaining the broad-spectrum activity of previous tetracyclines [17,27,28]. The antibacterial spectrum of newer agents comprises several resistant bacteria, including those resistant to older tetracyclines. Sarecycline is considered as a narrow-spectrum tetracycline due to highly selective antibacterial activity against *Cutibacterium acnes* [30]. Exploratory research identified non-antibiotic properties of several tetracyclines, particularly anti-inflammatory and neuroprotective effects of minocycline and sarecycline, possibly attributed partly to their inhibition of microglial activation and in part by modulating oxidative stress, however, the exact mechanisms are not well elucidated and understood [31-33]. Recently, the novel tetracyclines-exploiting strategy for neuroprotection based on their antiamyloidogenic, anti-inflammatory, antiapoptotic and antioxidant activities has emerged for the treatment of Alzheimer's and Parkinson's diseases. Nevertheless, challenges of repurposing tetracyclines further hampered by safety issues, such as antibiotic-induced alteration of microbiota in gut and consequent dysbiosis, and development and spread of AMR due to long-term antibiotic use.




Figure 1. Mechanism of action of tetracyclines

The tetracyclines reversibly bind to the 30S subunit of the bacterial ribosome thereby prevents binding of acyl-transfer RNA (tRNA) to the ribosome. Thus, tetracyclines by inhibiting protein synthesis that stops growth and replication of the bacterial organism leading to bacteriostatic effect.

2.4. Tigecycline

Tigecycline is a unique glycylicycline antibiotic approved by the US FDA in 2005. It has susceptibility to clinically important MDR nosocomial and community-acquired bacterial pathogens and also against a broad range of Gram-negative and Gram-positive bacteria species. It inhibits the translation elongation step by binding to the ribosome 30S subunit (five times stronger than other tetracyclines).andIt also prevents aminoacylated tRNA accumulation in the ribosomal A site even in the presence of ribosomal protecting efflux pumps [28,34].MDR Gram-negative pathogens, such as A. baumannii and ESBL producing K. pneumoniae and E. coli are highly susceptible to tigecycline. It is also active against VRE, MRSA, penicillin-resistant Streptococcus pneumonia, anaerobes, and 'atypical' bacteria. However, it is not active against P.aeruginosa and Proteus, Morganella, and Providencia species [35]. Moreover, parenteral tigecycline was poorly tolerated and ineffective when tried as an agent in multidrug regimens for salvage therapy of Mycobacterium abscessusinfection and alternative option of oral formulation is not available. Therefore, omadacycline and eravacycline may represent a new therapeutic option for treating M. abscessus complex infections [36,37]. Recent reports show that tigecycline remained active against Gram-positive and Gram-negative bacteria, at the same time resistant strains such as fluoroquinolone and broad spectrum β -lactam-resistant Enterobacteriaceae, vancomycin-resistant E. faecium, has increased during the same period [34,35]. Evidence exist that tigecycline is highly effective for the treatment of severe Clostridioides difficile infections **in those previous generation tetracyclines are ineffective**. In addition, Coxiella spp.,Rickettsia spp., and MDR Neisseria gonorrhoea strains showed *in vitro* susceptibility to tigecycline, indicating its possible use in the treatment of such infections [38].

Tigecycline is indicated for the treatment of complicated skin and skin structure infections (SSSIs) caused by E. coli, E. faecalis (vancomycin-susceptible isolates), Staph. aureus (MSSA and MRSA isolates), S. agalactiae, S. anginosusgrp. (includes S.anginosus, S. intermedius, and S. constellatus), S. pyogenes, E. cloacae,K. pneumoniae, and B. fragilis. It is also indicated for the treatment of complicated intra-abdominal infections (cIAls) caused by Citrobacterfreundii, E. cloacae,E. coli, K. oxytoca, K. pneumoniae, E. faecalis(vancomycin-susceptible isolates), Staph. aureus (MSSA and MRSA isolates), S. anginosus grp. (includes S. anginosus, S. intermedius, and S.constellatus), B. fragilis, B. thetaiotaomicron, B. uniformis,B. vulgatus, Cl. perfringens, and Peptostreptococcus micros. Further, it is also approved **fro** the treatment of community-acquired bacterial pneumonia (CABP) caused by S. pneumoniae (penicillinsusceptible isolates), including cases with concurrent bacteremia, H. influenza (beta-lactamase negative isolates), and L. pneumophila[37,38]. It is administered as intravenous infusion for a duration of about 30–60 min every 12 h. The recommended initial dose of tigecycline is 100 mg followed by 50 mg every 12 h and duration of treatment with tigecycline for cSSTIs or cIAls and CAP is 5–14 and 7–14 days, respectively (Table 2) [39,40]. As the tetracyclines, tigecycline also exhibits the same adverse events such as gastrointestinal symptoms commonly nausea, vomiting, and other rare events including injection site irritation, pain and swelling,**and**anorexia[41,42]. It is to be noted that tigecycline has no approved indication for treatment of diabetic foot infection or for hospital-acquired or ventilator-associated pneumonia, in which high rate of mortality is reported [39]. The US FDA has already warned that there is an increased risk of death resulted from complications of infection, worsening infections, or other underlying medical conditions when intravenous tigecycline is used for approved and non-approved uses. Presently, tigecycline is a reserve antibiotic for use in situations when alternative antibiotic therapies are not appropriate [39,41,43]. Importantly, advice and concordance between health care professionals,**and** patients and their caregivers **is** highly essential for using tigecycline in such situations.

Comment [w5]: Any abbreviation must be mentioned in full name for the first time

Comment [w6]: Transferred to upward GIT symptoms

2.5 Omadacycline

Omadacycline, a novel aminomethyl tetracycline antibiotic, has been developed to combat the AMR resistance to earlier tetracyclines [43]. It possesses excellent activity against many bacterial species and reversibly binds to the 30S ribosomal subunit and inhibits protein synthesis. Due to reversible binding, they act as bacteriostatic agents. *In vitro* omadacycline has demonstrated bactericidal activity against Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis [44]. Mycobacterium abscessus complex (MABC)-non-tuberculous mycobacteria that include (M. abscessus, M. bolletii, and M. massiliense) which are the major cause of human pulmonary or skin and skin structure infections (SSSI) has acquired resistance to older tetracyclines but now sensitive to omadacycline [45-47]. The characteristics of the omadacycline include broad-spectrum activity, and overcoming the two primary mechanisms of tetracycline resistance, efflux and ribosome protection. It has shown efficacy and is well-tolerated when used for acute bacterial SSTIs and CAP [17,27,48]. The other two pharmacological benefits include oral bioavailability and lack of glycylicide-induced dose-limiting nausea and vomiting [43]. Omadacycline has minimal known drug-drug interactions, and should be administered in a fasting state, avoiding dairy and cation-containing products for at least 4 h after dosing [48]. The chemical structure of omadacycline is similar to tigecycline, and it is the derivative of minocycline [26,27]. With increasing awareness and surveillance of antibiotic utilization, antimicrobial stewardship programs has continuously been considering utilization of omadacycline as potential therapeutic option in the treatment of infections caused by antibiotic-resistant and MDR Gram-positive bacteria, including MRSA, VRE, including vancomycin-resistant E. faecium and E. faecalis, penicillin and tetracycline-resistant S. pneumoniae and S. viridans, erythromycin-resistant S. agalactiae. Moreover, omadacycline is also equally effective against Gram-negative pathogens, such as E. coli, K. pneumoniae, P. aeruginosa, E. cloacae, H. influenzae, Citrobacter spp., and P. mirabilis. And its antibacterial spectrum is also extended to respective ESBL and carbapenem resistant Enterobacteriaceae (CRE) phenotypes as well as ceftazidime resistant strains [26,46]. It also exhibits potent *in vitro* activity against non-mycobacterial atypical organisms, including Mycoplasma pneumoniae and hominis, Legionella pneumophila, and Chlamydia pneumoniae. Omadacycline could positively affect hospitalization-associated expenses for both bacterial CAP and acute bacterial SSTIs by providing another oral agent active against resistant Gram-positive pathogens [48].

It is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by S. pneumoniae, Staph. aureus (MSSA isolates), H. influenzae, H. parainfluenzae, K. pneumoniae, L. pneumophila, M. pneumoniae, and C. pneumoniae. Further, it is also indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by Staph. aureus (MSSA and MRSA isolates), Staph. lugdunensis, S. pyogenes, S. anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), E. faecalis, E. cloacae, and K. pneumoniae [48,49]. It is indicated for CABP given once-daily oral and intravenous administration [48,49]. For injection, omadacycline is available as single-dose vials containing 100 mg of omadacycline as sterile lyophilized powder. It is recommended intravenous dose of 200 mg should be administered slowly as an infusion over 60 min duration whereas that of 100 mg dose is administered over 30 min (Table 2) [44,49,]. Besides, omadacycline is an ideal choice even in out-patient and ambulatory care settings wherein such treatment option enable health care facilities to discharge patients who cannot take other oral antibiotics and reduce the duration of hospital stay. Adding to this, such therapeutic option allow for treatment on an

Comment [w7]: It acts not they

Comment [w8]: Good or high oral bioavailability
Must be mentioned

Comment [w9]: Susceptible organisms
No need to repeat pathogens mentioned upward

Table 2. Antibacterial spectrum, pharmacokinetics, dosage regimen, safety, and indications of newer tetracyclines

Drug name	Spectrum	Pharmacokinetics ($t_{1/2}$, T_{max} , C_{max} , MIC)	Dose and duration	Side effects	Indications
Tigecycline	Broad spectrum	$t_{1/2}$: 1.05-2.34 h C_{max} : 0.42-11.1 $\mu\text{g/mL}$ T_{max} : 2.0-2.8 h MIC: $\leq 2\mu\text{g/mL}$	Initial dose of 100 mg followed by 50 mg every 12 h is 5–14 and 7–14 days	Nausea, vomiting, injection site irritation, pain, swelling, and anorexia	cSSTIs cIAIs(cholecystitis, gangrenous perforated diverticulitis, appendicitis, peritonitis) CAP
Omadacycline	Gram-positive and negative aerobic pathogens	$t_{1/2}$: 16-17 h T_{max} : 2.5 h C_{max} : 0.3-4.5 $\mu\text{g/mL}$ MIC: 0.06 and 0.125 $\mu\text{g/mL}$	Intravenous dose of 200 mg infusion over 60 min, 100 mg dose is administered over 30 min	Nausea, vomiting, diarrhoea, tooth discoloration, inhibition of bone growth, increased heart rate, increased hepatic enzymes	cSSTIs CAP UTIs
Eravacycline	Broad-spectrum against aerobic and anaerobic Gram-negative and positive bacteria, except <i>P. aeruginosa</i> and <i>Burkholderia cepacia</i>	$t_{1/2}$: 20 h C_{max} : 1 h T_{max} : 1.5-2 h MIC: 0.5-2 $\mu\text{g/mL}$	1mg/kg every 12 h, i.v. infusion approximately over 60 min every 12 h for 4 to 14 days	ISRs, nausea, vomiting, diarrhoea hypotension, and wound dehiscence	cIAIs(diverticulitis, appendicitis, intra-abdominal abscess, cholecystitis, gastric and duodenal perforation, intestinal perforation, and peritonitis)
Sarecycline	Narrow-spectrum activity against aerobic and anaerobic Gram-negative bacteria, limited activity against Gram-positive organisms	$t_{1/2}$: 21-22 h T_{max} : 1.5-2.0 h C_{max} : 1.5-2.0 h MIC: 0.5 $\mu\text{g/mL}$	0.75, 1.5, 3.0 mg/kg, OD, for 12 weeks 33 to 54 kg: 60 mg 55 to 84 kg: 100 mg 85 to 136 kg: 150 mg No dose adjustments for hepatic/renal impairment	Nausea, vomiting, abdominal pain and discomfort, nasopharyngitis, sunburn, vulvovaginal candidiasis, and vulvovaginal mycotic infection	Acne vulgaris(inflammatory skin lesions of non-nodular with moderate-to-severe acne vulgaris in patients who are 9 years old and above)

CAP: Community acquired pneumonia; cIAIs: Complicated intra-abdominal infections; cSSTIs: Complicated skin and soft tissue infections; MIC: Minimum inhibitory concentration; UTI: Urinary tract infection

outpatient basis, which could further reduce cost and risk of hospitalization [50]. Overall, omadacycline is well tolerated, although nausea and vomiting are frequently reported [49]. Notwithstanding this favorable safety profile, omadacycline caused a moderate increase in heart rate during the treatment period possibly effects mediated through muscarinic M2 receptors [49,51]. On the other hand, omadacycline reported to cause an increase in hepatic enzymes, albeit relatively low. Indeed, it shares many of the undesirable side effects of tetracyclines, such as tooth discoloration, inhibition of bone growth, etc., [49].

2.6 Eravacycline

Eravacycline is a novel broad-spectrum tetracycline and that has been developed to overcome tetracycline resistance. It is indicated for the treatment of intra-abdominal infections caused by susceptible microorganisms and has a broad antibacterial spectrum that can cover all common clinical pathogens except *P. aeruginosa*, including Gram-negative and Gram-positive aerobic and anaerobic strains [52]. It is a totally synthetic fluorocycline specifically designed to overcome tetracycline-acquired resistance associated with ribosomal protection mechanisms and efflux pumps [53]. It also shows good antibacterial activity against MDR bacteria, including Enterobacteriaceae and *A. baumannii*, expressing extended-spectrum. It is more effective than omadacycline against Gram-negative and broad-spectrum beta-lactamase-producing bacteria [53]. It is particularly active against all rapidly growing Mycobacterium species which includes *M. abscessus* subsp. *abscessus*, *M. abscessus* subsp. *massiliense*, *M. chelonae*, *M. immunogenum*, *M. fortuitum*, and *M. mucogenicum* groups [54]. It shares the same mechanism of action as other tetracyclines and the main effects are bacteriostatic and reversible, with some bactericidal activity against certain bacterial species. It was previously believed that eravacycline could be utilized in complicated urinary tract infections (cUTI), but failed to show efficacy in comparison to carbapenems. Despite this, it is characterized by as a broad-spectrum antimicrobial with coverage of several resistant strains, such as MRSA, VRE, CRE, tetracycline-resistant bacteria, as well as *A. baumannii* [55]. It has extended spectrum of antimicrobial activity against *E. coli*, *K. pneumoniae*, *Citrobacter freundii*, *E. cloacae*, *Streptococcus anginosus* group, *Cl. perfringens*, *Bacteroides* species, and *Parabacteroides distasonis*, *Klebsiella oxytoca*, *Enterococcus faecalis*, *Enterococcus faecium*, *Staph. aureus*. However, it is not indicated for the treatment of cUTI.

It is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by *E. coli*, *K. pneumoniae*, *Citrobacter freundii*, *E. cloacae*, *K. oxytoca*, *E. faecalis*, *E. faecium*, *Staph. aureus*, *S. anginosus* group, *Cl. perfringens*, *Bacteroides* species, and *Parabacteroides distasonis* in patients 18 years or older [56]. In practice, it should be used only to treat or prevent infections that are suspected to be caused by susceptible bacteria. It has advantage over other new tetracyclines as both oral and intravenous formulations are available. The recommended dosage regimen is 1 mg/kg every 12 h for slow intravenous infusion over 60 min every 12 h. The commonly reported adverse effects are infusion site reactions, nausea, vomiting, diarrhea, hypotension, and wound dehiscence. Though well studied for antibacterial activity against infections in adults, its safety and effectiveness in paediatrics have not been established. Moreover, dosage adjustment is warranted in patients with severe hepatic and/or renal impairment (Table 2) [57,58]. To some extent, resistance in some bacteria to eravacycline is associated with up-regulated, non-specific intrinsic MDR efflux, and target-site modifications, such as 16s rRNA or certain 30S ribosomal proteins [53]. It approved only for the treatment of CAP and acute SSTIs, such as appendicitis, cholecystitis, diverticulitis, gastric and duodenal perforation, intra-abdominal abscess, intestinal perforation, and peritonitis. Recent clinical trials also demonstrated its use in pyelonephritis and cystitis. Though it has very less drug-drug interactions, it should

Comment [w10]: Correct the structure of the sentence.

Comment [w11]: Correct the structure of the sentence

Comment [w12]: The full name before this abbreviation as it isn't mentioned before

be avoided with dairy and divalent cation containing products for at least 4 h of duration after the dosing[52,56,58].

2.7 Sarecycline

Sarecycline is a novel, narrow-spectrum, once-daily, oral tetracycline class antibiotic approved in October 2018. It has potent activity against Gram-positive bacteria, including activity against multiple strains of *Cutibacterium acnes* (*C. acnes*), an anaerobic Gram-positive bacterium that causes acne lesions and possesses anti-inflammatory properties similar to other tetracyclines. Most of the older tetracyclines have broad-spectrum antibacterial activity, contrary to that sarecycline is less potent due to its activity against enteric aerobic Gram-negative bacteria and anaerobic bacteria is minimal [30,59-61]. Owing to its narrow-spectrum antibacterial activity, sarecycline is associated lower risk of potential adverse effects, thus making it a potential therapeutic choice for definitive treatment among antibiotics, including tetracyclines. In addition to this, sarecycline had shown low susceptibility to resistance over other tetracyclines. Importantly, it is active against erythromycin- and clindamycin-resistant *C. acnes* strains as well as tetracycline-resistant *Staph. aureus* [59,64]. It is well known that acne vulgaris affects almost everyone, particularly during teenage and young adult years, though over 40% of individuals still suffer from acne in adulthood as well. Keeping in view of this, sustained efforts have been made to identify the most safe, well-tolerated, and effective treatments. [62,63,65]. Despite many studies being conducted to determine the antimicrobial spectrum of sarecycline compared to other tetracyclines, it is still a narrow spectrum antibiotic with a purpose to reduce and tackle AMR [30,64]. It exerts its antimicrobial effect mainly as a ribosomal protein synthesis inhibitor. Intriguingly, it has a unique mechanism of action due to it has the longest and largest chemical moiety attached at the carbon-7 (C7) position of ring D of the four-ring core. Thus exerting antibiotic effect by binding to the decoding centre of the 30S subunit of the bacterial ribosome, thereby inhibiting mRNA to protein translation [29,30,66]. It is active against both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains of *S. aureus* as well as *S. epidermidis*, but less active than doxycycline and minocycline by twofold. Indeed, it is more active than tetracycline and doxycycline against *S. pyogenes*, *S. agalactiae*, *E. faecalis*, and *E. faecium* (both vancomycin susceptible and resistant).

It is used as a narrow-spectrum antibiotic specifically indicated for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne in patients 9 years old and above [62,63,67]. The treatment regimen for acne includes one sarecycline tablet per day (equivalent to 1.5mg/kg/day) administered orally as 60 mg, 100 mg, or 150 mg with or without food for duration up to 40 weeks (Table 2) [60,67,68]. Patient education and medication adherence is highly essential while taking sarecycline. It is recommended that patients should ingest the tablet at the same time each day at least one hour before or two hours after eating for beneficial and desirable therapeutic outcome. It is recommended not to use this drug beyond 12 months since its safety beyond 12 months has not been established yet [67]. The common adverse effects of sarecycline include nausea, bloody stools, stomach irritation, phototoxic adverse effects, light-headedness, vertigo, dizziness, and abnormal pressure in the brain. Apart from threat of developing AMR, the use of few of the oral antibiotics is often limited by their vestibular side effects, such as dizziness and vertigo. It is reported that sarecycline poorly crosses blood-brain barrier due to its weak lipophilicity when compared with other tetracyclines that may explain relatively lower rates of vestibular-related side effects observed in clinical trials [69]. In animal toxicity studies, it has shown skeletal defects in offspring, decreased fertility, and decreased spermatogenesis. Therefore, it is contraindicated in pregnant and breastfeeding women due to the risk of teratogenic effects [67].

Comment [w13]: correct

CONSENT

It is not applicable.

ETHCAL APPROVAL

It is not applicable.

3. CONCLUSIONS

Emergence and tackling of antimicrobial resistance is a crisis for the health and wealth of the nations across the world. Irrational and inappropriate use of antibiotics is one the main cause of development and spread of AMR. Owing to this, most of the microorganisms are evolving due to selection pressure, developing resistance, and rendering antibiotics ineffective in treating many infectious diseases. The discovery and emergence of newer tetracyclines has shown remarkable effect against bacteria that are resistant to previous antibiotics including older tetracyclines. Recently approved tetracyclines, omadacycline, eravacycline, and sarecycline as well as tigecycline, have the advantage of a superior potency against both Gram-positive and Gram-negative aerobic as well as anaerobic MDR bacteria. These drugs also have a broad spectrum of activity which is very advantageous in treating many infectious diseases. These newer tetracyclines act like magic bullets, particularly against antibiotic-resistant pathogens and 'superbugs' and had shown promising results in treating infections caused antibiotic-resistant, MDR, and XDR bacteria. Through these are new antibiotics categorized as third generation tetracyclines, their discovery, development, and subsequent approval with specified indications are important milestone in medicine, particularly, to rationalize appropriate use and to minimize development and spread of AMR. Essentially, these agents serve as leading molecules and maneuver for discovery and development of newer antibiotics in the post-antibiotic era. Inarguably, continuous surveillance on antibiotic utilization and implementation of antibiotic stewardship programs are warranted to help select appropriate treatment, to optimize therapeutic outcomes, to minimize AMR, and to sustain therapeutic efficacy for future.

Comment [w14]: Correct the language

REFERENCES

1. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. *Curr Opin Microbiol.* 2019;51:72-80.
2. Spagnolo F, Trujillo M, Dennehy JJ. Why do antibiotics exist? *mBio.* 2021;12(6):e0196621.
3. Christensen SB. Drugs that changed society: history and current status of the early antibiotics: salvarsan, sulfonamides, and β -lactams. *Molecules.* 2021;26(19):6057.
4. Zipfel PF, Skerka C. From magic bullets to modern therapeutics: Paul Ehrlich, the German immunobiologist and physician coined the term 'complement'. *Mol Immunol.* 2022;150:90-98.
5. Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A review on antibiotic resistance: alarm bells are ringing. *Cureus.* 2017;9(6):e1403.
6. Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran TB, Dhama K, Ripon MKH, Gajdacs M, Sahibzada MUK, Hossain MJ, Koirala N. Antibiotic

- resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. *J Infect Public Health*. 2021;14(12):1750-1766.
7. Pasupulati H, Avadhanula V, Mamilla A, Bamini M, Padi SSV. Antibiotic prescribing practices in primary care settings using 2019 WHO AWaRe framework. *J. Pharm. Res. Int*. 2021;33(37A):58-6.
 8. Peddireddy M, Mahin J, Uppu A, Padi SSV. Hospital antibiotic prescribing pattern in general surgery specialty: analysis based on the WHO Access, Watch and Reserve (AWaRe) classification. *J Pharma Res Int*. 2021;33(41B):7–19.
 9. Mahin J, Peddireddy M, Mangalapalli V, Padi SS. Antibiotic prescribing practice in chronic kidney disease patients in a tertiary care teaching hospital: analysis based on 2019 WHO AWaRe classification. *Int J Life Sci Pharm Res*. 2021;11(4):P49-P57.
 10. Klein EY, Milkowska-Shibata M, Tseng KK, Sharland M, Gandra S, Pulcini C, Laxminarayan R. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data. *Lancet Infect Dis*. 2021;21(1):107-115.
 11. Laxminarayan R, Van Boeckel T, Frost I, Kariuki S, Khan EA, Limmathurotsakul D, Larsson DGJ, Levy-Hara G, Mendelson M, Outterson K, Peacock SJ, Zhu YG. The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. *Lancet Infect Dis*. 2020;20(4):e51-e60.
 12. Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, Goyal JP, Tadeipalli K, Mathur P, Venkateswaran R, Venkatasubramanian R, Khadanga S, Bhattacharya S, Mukherjee S, Baveja S, Sistla S, Panda S, Walia K. Secondary infections in hospitalized COVID-19 Patients: Indian experience. *Infect Drug Resist*. 2021;14:1893-1903.
 13. Terreni M, Taccani M, Pregnotato M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. *Molecules*. 2021;26(9):2671.
 14. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, Goossens H, Laxminarayan R. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. *Proc Natl Acad Sci USA*. 2018;115(15):E3463-3470.
 15. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. (Accessed May 12, 2023). Available: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf
 16. AMR Research and surveillance Network, Indian Council of Medical Research, 2021. Annual report. (Accessed May 10, 2023). Available: https://main.icmr.nic.in/sites/default/files/upload_documents/AMR_Annual_Report_2021.pdf
 17. LaPlante KL, Dhand A, Wright K, Lauterio M. Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. *Ann. Med*. 2022;54(1):1686-700.
 18. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629-655.
 19. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2022;400(10369):2221-2248.
 20. Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. *Antimicrob Resist Infect Control*. 2019;8:137.
 21. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert

- proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012;18(3):268-81.
22. Hansson K, Brenthel A. Imagining a post-antibiotic era: a cultural analysis of crisis and antibiotic resistance. *Med. Humanit.* 2022;48(3):381-8.
 23. Ranjalkar J, Chandy SJ. India's National Action Plan for antimicrobial resistance - An overview of the context, status, and way ahead. *J Family Med Prim Care.* 2019;8(6):1828-1834.
 24. Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An Update on Eight "New" antibiotics against multidrug-resistant Gram-negative bacteria. *J Clin Med.* 2021;10(5):1068.
 25. Grossman TH. Tetracycline antibiotics and resistance. *Cold Spring Harb Perspect Med.* 2016;6(4):a025387.
 26. Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Hink R, Berry L, Schweizer F, Zhanel MA, Bay D. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. *Drugs.* 2020;80:285-313.
 27. Ramachandran R., Schaefer B. Tetracycline antibiotics. *ChemTexts.* 2021;7:1–42.
 28. Rusu A, Buta EL. The development of third-generation tetracycline antibiotics and new perspectives. *Pharmaceutics.* 2021;13(12):2085.
 29. Markley JL, Wencewicz TA. Tetracycline-Inactivating Enzymes. *Front Microbiol.* 2018;9:1058.
 30. Boyanova L. *Cutibacterium acnes* (formerly *Propionibacterium acnes*): friend or foe? *Future Microbiol.* 2023;18:235-244.
 31. Padi SS, Kulkarni SK. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. *Eur J Pharmacol.* 2008;601(1-3):79-87.
 32. Pabreja K, Dua K, Sharma S, Padi SS, Kulkarni SK. Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and antioxidant mechanisms. *Eur J Pharmacol.* 2011;661(1-3):15-21.
 33. Markulin I, Matasin M, Turk VE, Salković-Petrisic M. Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease. *J Neural Transm (Vienna).* 2022;129(5-6):773-804.
 34. Seputiene V, Povilonis J, Armalyte J, Suziedelis K, Pavilonis A, Suziedeliene E. Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria? *Medicina (Kaunas).* 2010;46(4):240-8.
 35. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. *J Antimicrob Chemother.* 2011;66(9):1963-71.
 36. Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL. In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of *Mycobacterium abscessus*. *Antimicrob Agents Chemother.* 2019;63(6):e00470-19.
 37. Zhang T, Du J, Dong L, Wang F, Zhao L, Jia J, Wang C, Cheng M, Yu X, Huang H. In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing *Mycobacteria*. *MicrobiolSpectr.* 2023;11(1):e0323822.
 38. TYGACIL® (tigecycline) FOR INJECTION for intravenous use. (Accessed May 12, 2023). Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s0211bl.pdf
 39. Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, Ghafouri Z, Maleki F. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *Eur J Clin Microbiol Infect Dis.* 2022;41(7):1003-1022.

40. Meagher AK, Ambrose PG, Grasela TH, Grosse JE. The pharmacokinetic and pharmacodynamic profile of tigecycline. *Clin. Infect. Dis.* 2005;41(Supplement_5):S333-40.
41. Paudel R, Nepal HP. Tigecycline: pharmacological concerns and resistance. *Int J Basic Clin Pharmacol.* 2020;;9(8):1296-300.
42. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. (Accessed May 12, 2023). Available: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline#>
43. Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. *Bioorg. Med. Chem.* 2016;24(24):6409-19.
44. Burgos, R.M.; Rodvold, K.A. Omadacycline: A novel aminomethylcycline. *Infect. Drug Resist.* 2019, 12, 1895–1915.
45. Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of omadacycline against nontuberculous Mycobacteria. *Antimicrob Agents Chemother.* 2021 Feb 17;65(3):e01947-20.
46. Rizzo AR, Moniri NH. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use. *BMC Infect Dis.* 2022;22(1):874.
47. Li A, He S, Li J, Zhang Z, Li B, Chu H. Omadacycline, eravacycline, and tigecycline express anti-mycobacterium abscessus activity in vitro. *MicrobiolSpectr.* 2023:e0071823.
48. Gallagher JC. Omadacycline: A modernized tetracycline. *Clin Infect Dis.* 2019;69(Suppl 1):S1-S5.
49. NUZYRA (omadacycline) for injection, for intravenous use. NUZYRA (omadacycline) tablets, for oral use. (Accessed May 14, 2023). Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf
50. Ektare V, Khachatryan A, Xue M, Dunne M, Johnson K, Stephens J. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. *J Med Econ* 2015; 18:1092–101.
51. Moran GJ, Chitra S, McGovern PC. Efficacy and safety of omadacycline versus linezolid in acute bacterial skin and skin structure infections in persons who inject drugs. *Infect Dis Ther.* 2022;11(1):517-531.
52. Meng R, Guan X, Sun L, Fei Z, Li Y, Luo M, Ma A, Li H. The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis. *Front Med (Lausanne).* 2022;9:935343.
53. Scott LJ. Eravacycline: A review in complicated intra-abdominal infections. *Drugs.* 2019;79(3):315-324.
54. Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of eravacycline against nontuberculous Mycobacteria. *Antimicrob Agents Chemother.* 2022;66(9):e0068922.
55. Wang H, Nguyen N, Cruz C. Eravacycline for the treatment of complicated intra-abdominal infections. *Adv. Dig. Med.* 2021;8(4):203-10.
56. XERAVA (eravacycline) for injection, for intravenous use. (Accessed May 14, 2023). Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
57. Eljaaly K, Ortwine JK, Shaikhomer M, Almangour TA, Bassetti M. Efficacy and safety of eravacycline: A meta-analysis. *J Glob Antimicrob Resist.* 2021;24:424-428.

58. Kong W, Deng T, Li S, Shu Y, Wu Y. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis. *BMC Infect Dis.* 2023;23(1):256.
59. Moore AY, Del Rosso J, Johnson JL, Grada A. Sarecycline: a review of preclinical and clinical evidence. *Clinical, Clin. Cosmet. Investig. Dermatology.* 2020:553-60.
60. Del Rosso JQ. Sarecycline and the narrow-spectrum tetracycline concept: Currently available data and potential clinical relevance in dermatology. *J Clin Aesthet Dermatol.* 2020;13(10):45-48.
61. Moore AY, Hurley K, Moore SA, Moore L, Zago I. Effect of Sarecycline on the Acne Symptom and Impact Scale and Concerns in Moderate-to-Severe Truncal Acne in Open-Label Pilot Study. *Antibiotics (Basel).* 2023;12(1):94.
62. Valente Duarte de Sousa IC. An overview of sarecycline for the treatment of moderate-to-severe acne vulgaris. *Expert OpinPharmacother.* 2021;22(2):145-154.
63. Pariser DM, Green LJ, Lain EL, Schmitz C, Chinigo AS, McNamee B, Berk DR. Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-label study and a phase I phototoxicity study. *J Clin Aesthet Dermatol.* 2019;12(11):E53-E62.
64. Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. *Antimicrob Agents Chemother.* 2018;63(1):e01297-18.
65. Marson JW, Baldwin HE. An overview of acne therapy, part 1: topical therapy, oral antibiotics, laser and light therapy, and dietary interventions. *Dermatol. Clin.* 2019;37(2):183-93.
66. Lomakin IB, Devarkar SC, Patel S, Grada A, Bunick CG. Sarecycline inhibits protein translation in *Cutibacterium acnes* 70S ribosome using a two-site mechanism. *Nucleic Acids Res.* 2023;51(6):2915-2930.
67. SEYSARA™ (sarecycline) tablets for oral use. (Accessed May 14, 2023). Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209521s000lbl.pdf
68. Deeks ED. Sarecycline: first global approval. *Drugs.* 2019;79:325-9.
69. Grada A, Del Rosso JQ, Moore AY, Stein Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem RJ, Tanaka SK, Bunick CG. Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity. *Front Med (Lausanne).* 2022;9:1033980.